IR News

Mar. 02, 2011Print(PDF/95KB)Finances

Dainippon Sumitomo Pharma Co., Ltd. Announces Issuance of Unsecured Straight Bonds

Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) today announced that it has determined the terms and conditions for the issuance of its 1st, 2nd and 3rd Series of Unsecured Straight Bonds. The terms and conditions are as outlined below.

1. Series of the Bonds 1st Series of Dainippon Sumitomo Pharma Co., Ltd. Unsecured Straight Bond (with inter-bond pari passu clause) 2nd Series of Dainippon Sumitomo Pharma Co., Ltd. Unsecured Straight Bond (with inter-bond pari passu clause) 3rd Series of Dainippon Sumitomo Pharma Co., Ltd. Unsecured Straight Bond (with inter-bond pari passu clause)
2. Aggregate Nominal Amount 10 billion yen 30 billion yen 10 billion yen
3. Denomination of each Bond 100 million yen
4. Issue Price 100% of the principal amount
5. Redemption Price 100% of the principal amount
6. Coupon Rate 0.534% per annum 0.782% per annum 1.106% per annum
7. Offering Period March 2, 2011
8. Payment Date March 8, 2011
9. Maturity Date March 7, 2014 March 8, 2016 March 8, 2018
10. Method of Redemption Bullet maturity (retirement by purchase is possible)
11. Interest Payment Dates March 8 and September 8 of each year
(First interest payment date: September 8, 2011)
12. Purpose of Funds Funds for repayment of loans
13. Rating A (Rating and Investment Information, Inc.)
14. Joint Lead Managers Daiwa Securities Capital Markets Co. Ltd.
Nomura Securities Co., Ltd.
Nikko Cordial Securities Inc.
15. Fiscal Agent Sumitomo Mitsui Banking Corporation

This press release has been prepared for the purpose of publicly announcing DSP's issuance of straight bonds and not for the purpose of soliciting investment or engaging in any other similar activities in any region including the United States or Canada. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act.